1、NOWNEXTWhat to do Now, What to do NextCovid-19: MedTech industry April 2020 Leading with Leading with Agility Agility and Responsible and Responsible Innovation Innovation inin Response to Response to COVIDCOVID- -1919 NOWNEXTWhat to do Now, What to do NextCovid-19: 2 COVID-19 is a global crisis, ev

2、olving at unprecedented speed and scale. The MedTech industry is challenged as never before to re-imagine the design of mission critical devices and dramatically ramp-up production capacity. Front-line manufacturers of ventilators, PPE, beds, and other essential equipment need to provide their produ

3、cts to clinicians and patients within days. Simultaneously, the regulatory environment is adapting at breakneck pace, foregoing traditional processes to achieve speed-to-patient. Beyond COVID-19, patients and clinicians will likely have new expectations of how they interact with medical devices. As

4、we emerge from this global crisis, a new era for how MedTech serves the needs of clinicians and people will begin. Leading with Agility and Responsible Innovation in Response to Covid-19: MedTech Industry Anchor ResponseCopyright 2020 Accenture. All rights reserved. MedTech companies should tackle t

5、he challenges presented by COVID-19 with a mindset of responsible innovation, which is one focused on agility, affordability, and outcomes. Diagnostics are the frontline to stop COVID-19s spread. Lack of early detection contributed to rampant spread. Achieving widespread testing, testing efficiency,

6、 and ongoing monitoring is essential to restart economies, safely. COVID-19 is fueling unprecedented product innovation. Inventive engineers and clinicians are retrofitting or reimagining products in limited supply for new and expanded use. Centers for Medicare India relies on China for most of thei

7、r finished goods while Europe is dependent on EU cross-border supply chains. Companies must pivot their supply chains to address these impacts. End-to-end transparency is needed to make informed, agile decisions. Companies must build greater resilience within their supply networks. 1 2 Ventilator pr

8、oduction increased from 700 per week in 2019 to 2,000-3,000 per week during the COVID-19 crisis, eventually increasing to 7,000 per week. Currently, the U.S. is projected to have a gap of 75,000 ventilators.2 1Source: Advanced Medical Technology Association Survey: “Tens of Thousands of Life-saving

9、Ventilators on Deck to Combat COVID-19”. April 1, 2020. 2Source: Global Data Review: “Ventilator Crisis During Coronavirus Outbreak as Over 880000 are Needed”. March 23, 2020. Lifesaving MedTech products are in unprecedented demandPPE, diagnostics, ventilators, and IV products, to name a few. Produc

10、tion volume and throughput is experiencing an exponential surge which requires a collective industry response seemingly overnight. MedTech companies have responded by ramping up their production capacity. However, as the pandemic spreads and disrupts global supply chains, demand for these products i

11、s quickly outpacing supply. How will demand be met during acute shortages? How can the industry manufacture faster and at greater volume while maintaining quality? How will companies continue to deliver needed products with logistics disruptions? Leading with Agility and Responsible Innovation in Re

12、sponse to Covid-19: MedTech Industry Anchor Response 11Copyright 2020 Accenture. All rights reserved. AssureAssuresupply there is no time to make systematic changes. However, you can adopt a new mindset of responsible innovation in your response, along with the need for agility, affordability, and o

13、utcomes. As we emerge from this crisis, preserve and embed newly developed capabilities back into your organization. 1 How much of a mindset change is required in my organization? 2 What innovation can be sustained after the crisis? 3 And critically, how is your business preparing for the next crisi

14、s? Moving ahead: Moving ahead: Continue to unleash a new mindset of Continue to unleash a new mindset of responsible innovationresponsible innovation As the world emerges from this crisis, MedTech should incorporate learnings from the pandemic into a new way of thinking and working. OUR PERSPECTIVE

15、CONSIDER Leading with Agility and Responsible Innovation in Response to Covid-19: MedTech Industry Anchor Response 15Copyright 2020 Accenture. All rights reserved. How can we help you?How can we help you?Here are just a few ways.Here are just a few ways. Virtualize workforce & business continuity El

16、astic digital workplace - collaboration, virtual engagement Workforce planning & scenario modeling Virtual training / proctoring Redefine the Product Agile coaching, design thinking, and speed to value methodology Product development and service blueprinting Virtualization of product design & engine

17、ering (digital twin / digital thread) Digital product companion or therapy management apps Assure Supply & Delivery Supply chain disruption analyzer and scenario modelling Rapid response control tower MedTech / supplies marketplace for COVID-19 Advance Diagnostics & Monitoring Digital diagnostics ap

18、ps for COVID-19 and beyond Scale-up telemedicine solutions Design and build diagnostic networks across care providers, MedTech and payers End-to-end lab digitalization and automation (Lab of the future) Cloud-based diagnostic data and insights integration platforms Our IndustryAssets and Ecosystem P

19、artnerships can support your response efforts: Amazon Google Microsoft Our 100+ Global Delivery and Innovation Center Network sites and 20+ MedTech Centers of Excellence can supportresearch, design and prototyping: US Altitude Boston Pillar Columbus Mindtribe San Francisco ?Whatif! NewYork EU FJORD

20、Berlin designaffairs Munich ?Whatif! London Mackevision APAC FJORD Tokyo designaffairs Shanghai Accenture INTIENT Patient digital product suite that supports patients from pre- diagnosis through ongoing treatment Accenture Ventures portfolio of 200,000+ start-ups, 50+ ecosystem partners, and Accentu

21、re HealthTech Challenge start-ups Salesforce SAP Leading with Agility and Responsible Innovation in Response to Covid-19: MedTech Industry Anchor Response 16Copyright 2020 Accenture. All rights reserved. To help our clients navigate both the human and business impact of COVID-19, weve created a hub

22、of all of our latest thinking on a variety of topics. Each topic highlights specific actions which can be taken now, and what to consider next as industries move towards a new normal. From leadership essentials to ensuring productivity for your employees and customer service groups to building suppl

23、y chain resilience and much more, our hub will be constantly updated. Check back regularly for more insights. VISIT OUR HUB HERE Leading with Agility and Responsible Innovation in Response to Covid-19: MedTech Industry Anchor Response 17Copyright 2020 Accenture. All rights reserved. ContactsContacts

24、 Maximilian Schmid Managing Director MedTech Lead Global Sanskriti Thakur Senior Principal Global Life Sciences Research Lead Laura Westercamp Senior Manager COVID-19 Task Force Leader Tom Kawalec Managing Director MedTech Lead US William de Waard Managing Director MedTech Lead Netherlands DebmalyaC

25、hatterjee Managing Director MedTech Lead APAC TuncYorulmaz Managing Director MedTech Lead Japan Florian Schulz Managing Director MedTech Lead Austria, Switzerland, Germany, Russia Contributing Authors: Anne Marie OHalloran, Zeynep Waelchli, Florian Schulz, Jens Lauber, Floris Provoost, Dirk Schatten

26、berg, Sam Bavery and Greg Schulte Leading with Agility and Responsible Innovation in Response to Covid-19: MedTech Industry Anchor Response 18Copyright 2020 Accenture. All rights reserved. DISCLAIMER: This document is intended for general informational purposes only and does not take into account th

27、e readers specific circumstances, and may not reflect the most current developments. Accenture disclaims, to the fullest extent permitted by applicable law, any and all liability for the accuracy and completeness of the information in this presentation and for any acts or omissions made based on suc

28、h information. Accenture does not provide legal, regulatory, audit, tax or medical advice, and is not a manufacturer of medical devices. Readers are responsible for obtaining such advice from their own legal counsel or other licensed professionals. This document makes reference to marks owned by thi

29、rd parties. All such third-party marks are the property of their respective owners. No sponsorship, endorsement or approval of this content by the owners of such marks is intended, expressed or implied. Copyright 2020 Accenture All rights reserved. Accenture, its logo, and New Applied Now are tradem

30、arks of Accenture. AboutAccenture Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all b

31、usiness functionsunderpinned by the worlds largest delivery network Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With 509,000 people serving clients in more than 120 countries, Accenture

32、drives innovation to improve the way the world works and lives. Visit us at Special thanks to: Kenny Gibbons, Aran Bahl and the entire response team, including: Anthony Lynch, Julian Hohendorff, Paolo Apparuti, Deni Subasic, Tabea Schoefner, Taylor Hedrick, Masood Khan, Stefan Kalla, Stefan Rohrlack

33、, Jelle Klapwijk, Michael Schulz, Terry Benton, Domonique Bouldrick, Supriya Lagu, Frank Mueller and Penelope Bradshaw Related Content: Life Sciences COVID-19 Rapid Response: Leading with Integrity and Trust Leading with Agility and Responsible Innovation in Response to Covid-19: MedTech Industry Anchor Response 19